- Home
- MOLN vs MSLE Comparison
MOLN vs MSLE Comparison
Compare MOLN & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MOLN | MSLE |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.9M | 173.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MOLN | MSLE |
|---|---|---|
| Price | $5.02 | $11.27 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.38 | N/A |
| AVG Volume (30 Days) | 4.3K | ★ 61.1K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $285.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.36 | $10.64 |
| 52 Week High | $5.10 | $11.98 |
Technical Indicators
Market Signals| Indicator | MOLN | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 67.88 | N/A |
| Support Level | $3.50 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.17 | 0.00 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 97.80 | 0.00 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.